Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro-N-(2'-methyl-3'-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1'-biphenyl]-4-yl)benzamide. Structure-Activity Relationship and Preclinical Characterization.
Khedkar NR, Irlapatti NR, Dadke D, Kanoje V, Shaikh Z, Karche V, Shinde V, Deshmukh G, Patil A, Jachak S, Phukan S, Kizhakinagath PA, Gholve M, Bhankhede T, Daler J, Nemade HN, Budhe S, Pareek H, Yeshodharan R, Gupta R, Kalia A, Pandey D, Wagh A, Kumar S, Patil V, Modi D, Sharma N, Ahirrao P, Mehta M, Kumar H, Nigade P, Tamane K, Mallurwar S, Kuldharan S, Pawar S, Vishwase G, Bokan S, Singh M, Naik K, Ingawale S, Shankar R, Kamalakannan P, Venugopal S, George SK, Padiya KJ, Nemmani KVS, Gundu J, Bhonde M, Narasimham L, Sindkhedkar M, Shah C, Sinha N, Sharma S, Bakhle D, Kamboj RK, Palle VP. Khedkar NR, et al. Among authors: shah c. J Med Chem. 2021 Dec 9;64(23):17004-17030. doi: 10.1021/acs.jmedchem.1c01403. Epub 2021 Nov 29. J Med Chem. 2021. PMID: 34843241
Discovery of Novel, Potent, Brain-Permeable, and Orally Efficacious Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptor [4-(5-(4-Chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide]: Structure-Activity Relationship and Preclinical Characterization.
Sinha N, Karche NP, Verma MK, Walunj SS, Nigade PB, Jana G, Kurhade SP, Hajare AK, Tilekar AR, Jadhav GR, Thube BR, Shaikh JS, Balgude S, Singh LB, Mahimane V, Adurkar SK, Hatnapure G, Raje F, Bhosale Y, Bhanage D, Sachchidanand S, Dixit R, Gupta R, Bokare AM, Dandekar M, Bharne A, Chatterjee M, Desai S, Koul S, Modi D, Mehta M, Patil V, Singh M, Gundu J, Goel RN, Shah C, Sharma S, Bakhle D, Kamboj RK, Palle VP. Sinha N, et al. Among authors: shah c. J Med Chem. 2020 Feb 13;63(3):944-960. doi: 10.1021/acs.jmedchem.9b01569. Epub 2019 Dec 6. J Med Chem. 2020. PMID: 31755711
A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis.
Yamanaka H, Kamatani N, Tanaka Y, Hibino T, Drescher E, Sánchez-Bursón J, Rettenbacher M, Bhatia G, Gadve S, Shah C, Bakhle D. Yamanaka H, et al. Among authors: shah c. Rheumatol Ther. 2020 Mar;7(1):149-163. doi: 10.1007/s40744-019-00186-3. Epub 2019 Dec 12. Rheumatol Ther. 2020. PMID: 31833011 Free PMC article.
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration.
Singh R, Chauhan R, Saxena A, Shah A, Mondal L, Bakhle D, Shah C, Shah A, Deoghare S, Krishnan N, Godse N. Singh R, et al. Among authors: shah a, shah c. Indian J Ophthalmol. 2022 Aug;70(8):3008-3014. doi: 10.4103/ijo.IJO_2118_21. Indian J Ophthalmol. 2022. PMID: 35918962 Free PMC article. Clinical Trial.
Lower injection-site reactions and long-term safety, immunogenicity, and efficacy of etanercept biosimilar YLB113: Results from a post-hoc analysis of a double-blind, randomized, phase III comparative study and its open-label extension in patients with rheumatoid arthritis.
Yamanaka H, Tanaka Y, Hibino T, Unmesh G, Shah C, Bakhle D, Stefanidis D. Yamanaka H, et al. Among authors: shah c. Int J Rheum Dis. 2023 Jan;26(1):108-115. doi: 10.1111/1756-185X.14462. Epub 2022 Oct 17. Int J Rheum Dis. 2023. PMID: 36253032 Free PMC article. Clinical Trial.
Discovery of LNP1892: A Precision Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
Shukla MR, Sadasivam G, Sarde A, Sayyed M, Pachpute V, Phadtare R, Walke N, Chaudhari VD, Loriya R, Khan T, Gote G, Pawar C, Tryambake M, Mahajan N, Gandhe A, Sabde S, Pawar S, Patil V, Modi D, Mehta M, Nigade P, Modak V, Ghodke R, Narasimham L, Bhonde M, Gundu J, Goel R, Shah C, Kulkarni S, Sharma S, Bakhle D, Kamboj RK, Palle VP. Shukla MR, et al. Among authors: shah c. J Med Chem. 2023 Jul 27;66(14):9418-9444. doi: 10.1021/acs.jmedchem.3c00698. Epub 2023 Jul 13. J Med Chem. 2023. PMID: 37442941
1,289 results